Results 101 to 110 of about 104,627 (255)

PET imaging of microglia using PBR28suv determines therapeutic efficacy of autologous bone marrow mononuclear cells therapy in traumatic brain injury. [PDF]

Sci Rep, 2023
Bedi SS, Scott MC, Skibber MA, Kumar A, Caplan HW, Xue H, Sequeira D, Speer AL, Cardenas F, Gudenkauf F, Uray K, Srivastava AK, Prossin AR, Cox CS.   +13 more
europepmc   +1 more source

Bone Marrow Mononuclear Cell [PDF]

, 2020
openaire   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. [PDF]

Cochrane Database Syst Rev, 2022
Moazzami B, Mohammadpour Z, Zabala ZE, Farokhi E, Roohi A, Dolmatova E, Moazzami K.   +6 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Systemically injected bone marrow mononuclear cells specifically home to axially vascularized tissue engineering constructs. [PDF]

PLoS One, 2022
Eweida A, Flechtenmacher S, Sandberg E, Schulte M, Schmidt VJ, Kneser U, Harhaus L.   +6 more
europepmc   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells. [PDF]

Stem Cell Res Ther, 2023
Arango-Rodríguez ML, Mateus LC, Sossa CL, Becerra-Bayona SM, Solarte-David VA, Ochoa Vera ME, Viviescas LTG, Berrio AMV, Serrano SE, Vargas O, Isla AC, Benitez A, Rangel G.   +12 more
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source

Human Bone Marrow Mononuclear Cells Do Not Improve Limb Perfusion in the Hindlimb Ischemia Model. [PDF]

Stem Cells Dev, 2022
van Rhijn-Brouwer FCC, Gremmels H, Den Ouden K, Teraa M, Fledderus JO, Verhaar MC.   +5 more
europepmc   +1 more source